Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Malaysian Genomics Resource Centre Bhd PS Ratio?
Malaysian Genomics Resource Centre BhdXKLS:0155 44 PS Ratio is 4.47 as of Jul. 25, 2026, which is 6% below its 10-year median of 4.76. GuruFocus rates XKLS:0155 with a GF Score™ of 44/100 and a GF Value™ of RM0.31 (Fairly Valued). The stock has 3 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Malaysian Genomics Resource Centre Bhd ranks worse than 67% on this metric.
XKLS:0155's PS Ratio is ranked worse than 67% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.715
vs XKLS:0155: 4.47
Malaysian Genomics Resource Centre Bhd (XKLS:0155) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Malaysian Genomics Resource Centre Bhd PS Ratio Related Terms
Malaysian Genomics Resource Centre Bhd PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Malaysian Genomics Resource Centre Bhd PS Ratio Chart
Malaysian Genomics Resource Centre Bhd Annual Data
For the Diagnostics & Research subindustry, Malaysian Genomics Resource Centre Bhd's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Malaysian Genomics Resource Centre Bhd PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Malaysian Genomics Resource Centre Bhd's PS Ratio distribution charts can be found below:
* The bar in red indicates where Malaysian Genomics Resource Centre Bhd's PS Ratio falls into.
Malaysian Genomics Resource Centre Bhd PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Malaysian Genomics Resource Centre Bhd's Share Price of today is RM0.295. Malaysian Genomics Resource Centre Bhd's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Malaysian Genomics Resource Centre Bhd (XKLS:0155) has a PS Ratio of 4.47 as of Jul. 25, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. This is near median its historical median of 4.76. Over the past decade, Malaysian Genomics Resource Centre Bhd's PS Ratio has ranged from 0.93 to 150.00. According to the industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #134 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 67%.
Is Malaysian Genomics Resource Centre Bhd's PS Ratio too high?
Malaysian Genomics Resource Centre Bhd's current PS Ratio of 4.47 is near median its 10-year median of 4.76. Over the past 10 years, this metric has ranged from a low of 0.93 to a high of 150.00. The Medical Diagnostics & Research industry median PS Ratio is 2.72. Malaysian Genomics Resource Centre Bhd's value of 4.47 is 64.6% above this industry median. Based on the distribution chart, Malaysian Genomics Resource Centre Bhd ranks #134 out of 200 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Malaysian Genomics Resource Centre Bhd has a GF Score™ of 44/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Malaysian Genomics Resource Centre Bhd's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #134 out of 200 companies for PS Ratio. This places Malaysian Genomics Resource Centre Bhd in the lower half of its industry. The industry median PS Ratio is 2.72. Malaysian Genomics Resource Centre Bhd's value of 4.47 is 64.6% above this benchmark. Historically, Malaysian Genomics Resource Centre Bhd's own PS Ratio has ranged from 0.93 to 150.00 over the past decade. While the company's 10-year median is 4.76 vs. the industry median of 2.72, Malaysian Genomics Resource Centre Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.72, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Malaysian Genomics Resource Centre Bhd's current PS Ratio of 4.47 is 64.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Malaysian Genomics Resource Centre Bhd's current PS Ratio is 4.47, which is near median its own 10-year median of 4.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malaysian Genomics Resource Centre Bhd stock overvalued right now?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd (XKLS:0155) is currently considered Fairly Valued. The stock's GF Value™ is RM0.31, compared to a current price of RM0.30 — trading 4.8% below its estimated fair value. The current PS Ratio is 4.47, which is near median its 10-year median of 4.76 and 64.6% above the Medical Diagnostics & Research industry median of 2.72. Malaysian Genomics Resource Centre Bhd's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Malaysian Genomics Resource Centre Bhd (XKLS:0155), the current PS Ratio is 4.47 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be undervalued.
The current stock price of RM0.30 is trading 4.8% below its estimated GF Value™ of RM0.31.
GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Fairly Valued.
Key valuation signals for XKLS:0155:
PS Ratio: 4.47 (near median its 10-year median of 4.76)
GF Value™: RM0.31 vs. price of RM0.30 (4.8% below fair value)
Industry Position: 64.6% above the Medical Diagnostics & Research median (#134 of 200)
No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Malaysian Genomics Resource Centre Bhd Business Description
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
44GF Score
Get the complete analysis for XKLS:0155
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0155 has been successfully added to your 
